Gufic Biosciences Limited is charting a course for continuity at the top as its board approved the re-appointment of Pankaj Jayakumar Gandhi as Whole Time Director for a fresh five-year term. The term runs from September 7, 2026 to September 6, 2031, and remains subject to the shareholders’ approval at the company’s forthcoming 42nd Annual General Meeting. The move signals leadership stability as the company navigates a complex, highly regulated pharmaceutical landscape.
Gandhi brings a long arc of regulatory experience to the company, holding a Bachelor’s degree in Commerce from the University of Mumbai and boasting more than three decades of work liaising with regulatory authorities within the pharmaceutical sector. The company notes his track record in ensuring regulatory compliance and in maintaining effective coordination with statutory and regulatory bodies, a capability that has underpinned the firm’s operational efficiency and smooth functioning.
The board also disclosed that Gandhi is not debarred from holding the office of Director by SEBI or any other authority, reinforcing a governance framework built on compliance and integrity. His continued leadership is framed as a strategic asset for Gufic Biosciences as it pursues ongoing growth within a tightly regulated industry, where regulatory stewardship and cross-stakeholder coordination are central to execution.
As the company looks to translate regulatory discipline into sustained performance, industry observers will be watching the AGM for the formal confirmation of this extended tenure. The re-appointment underscores a philosophy of continuity at the executive level, pairing seasoned regulatory insight with the company’s broader growth ambitions.